4D Molecular Therapeutics FDMT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $85.21M+230,195% | $37K-99.8% | $20.74M+563% | $3.13M-82.7% | ||
| $195.7M+38.5% | $141.3M+45.5% | $97.09M+21.0% | $80.24M+30.8% | ||
| $49.06M+5.3% | $46.58M+27.6% | $36.5M+10.9% | $32.92M+17.5% | ||
| $244.76M+30.3% | $187.88M+40.6% | $133.59M+18.1% | $113.16M+26.6% | ||
| -$174.26M+7.2% | -$187.84M-66.4% | -$112.87M-2.6% | -$110.03M-54.3% | ||
| -204.5%+507,474pp | -507,678.4%-507,134pp | -544.2%+2,974pp | -3,517.7%-3,122pp | ||
| $19.44M-27.9% | $26.97M+124% | $12.03M+374% | $2.54M— | ||
| —— | -$160.87M-59.5% | -$100.84M+6.2% | -$107.49M-50.7% | ||
| —— | -$2.98-12.0% | -$2.66+19.9% | -$3.32-29.7% | ||
| -$169.57M+7.4% | -$183.19M-68.6% | -$108.66M-1.0% | -$107.63M-54.2% | ||
| -199%+494,904pp | -495,102.7%-494,579pp | -523.9%+2,917pp | -3,440.9%-3,054pp | ||
| -$174.26M+7.2% | -$187.84M-66.4% | -$112.87M-2.6% | -$110.03M-54.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is 4D Molecular Therapeutics's revenue?
- 4D Molecular Therapeutics (FDMT) generated $88.2M in revenue over the trailing twelve months, up 383560.9% year over year.
- Is 4D Molecular Therapeutics profitable?
- 4D Molecular Therapeutics is not currently profitable: it reported a net loss of $228.3M over the trailing twelve months, a -174314.2% net margin.
- What is 4D Molecular Therapeutics's earnings per share?
- 4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-3.86.
- Where does 4D Molecular Therapeutics's income statement data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
